Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence
Authors' conclusion
Over 100,000 users of the MiniMed™ 780G system have demonstrated consistency in achieving target control of glycemia.
Study context
- Population
- MiniMed 780G system users living in Europe, Middle East, and Africa (EMEA), CareLink Personal data August 2020–August 2023
- Participants
- 101,629 participants34 countries
- Outcome
- CGM-based endpoints, full cohort
Methodological detailsCareLink Personal data, full cohort and 12-month longitudinal cohort
- CareLink Personal data
- Full cohort and 12-month longitudinal cohort
Main finding
As reported in the abstract
- Mean time in range (TIR)
- 72.3%
- Glucose management indicator (GMI)
- 7%
- TBR70
- 2.0%
- TBR54
- 0.4%
- Users achieving GMI <7%
- 59.6%
- Users achieving TIR >70%
- 62.5%
- Users achieving TBR70 < 4%
- 88.4%
- Users achieving TBR54 < 1%
- 90.0%
Observational data: associations, not effects.
Further findings
Optimal setting users (≥95% of time with glucose target 100 mg/dL and active insulin time 2 h)
- TIR
- 78.8%
- Users reaching TIR >70%
- 86.3%
Self-reported age groups (≤15 and ≥56 years) and geographies
- Data showed consistency across self-reported age groups and geographies
TIR, 12-month longitudinal cohort
- TIR in first month
- 75.5%
- TIR over the 12-month period
- 73.3% or higher
Safety
Hypoglycaemia in optimal setting users
- TBR70
- 2.2%
- TBR54
- 0.4%
Original publication
Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →